Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ZAI LAB LIMITED

(ZLAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zai Lab : Phase Ib Study of Psoriasis Treatment in Australia Yields Positive Topline Results

10/21/2021 | 07:25am EST


ę MT Newswires 2021
All news about ZAI LAB LIMITED
12/05Zai Lab's Ovarian Cancer Treatment Added to China's National Reimbursement Drug List; S..
MT
12/03Citigroup Raises Price Target for Zai Lab to $231 From $217, Maintains Buy Rating
MT
12/03Zai Lab Says New Indication for Its Ovarian Cancer Drug Added to China's National Reimb..
MT
12/03Zai Lab Announces Inclusion of Zejula? in China's National Reimbursement Drug List for ..
CI
12/03ZAI LAB : Announces Inclusion of ZEJULA« (Niraparib) in China's National Reimbursement Dru..
PU
12/03ZAI LAB LTD : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
12/03Zai Lab Announces Inclusion of ZEJULA« (Niraparib) in China's National Reimbursement Dr..
AQ
11/30Zai Lab's Late-Stage Ovarian Cancer Trial Meets Primary Endpoint
MT
11/30Zai Lab Study for Ovarian Cancer Treatment Meets Primary Endpoint
DJ
11/30Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA« (Nirapar..
GL
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations
Financials (USD)
Sales 2021 152 M - -
Net income 2021 -609 M - -
Net cash 2021 1 397 M - -
P/E ratio 2021 -9,65x
Yield 2021 -
Capitalization 6 174 M 6 174 M -
EV / Sales 2021 31,5x
EV / Sales 2022 17,0x
Nbr of Employees 1 194
Free-Float 99,9%
Chart ZAI LAB LIMITED
Duration : Period :
Zai Lab Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZAI LAB LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 64,04 $
Average target price 196,69 $
Spread / Average Target 207%
EPS Revisions
Managers and Directors
Ying Du Chairman & Chief Executive Officer
Tao Fu President, Chief Operating Officer & Director
Billy Cho Chief Financial Officer
Ning Xu Executive VP & Head-Clinical Operations
James Yan Chief Operating Officer-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ZAI LAB LIMITED-51.70%6 174
CSL LIMITED4.63%95 233
WUXI BIOLOGICS (CAYMAN) INC.-6.71%56 209
SAMSUNG BIOLOGICS CO.,LTD.9.08%50 311
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-6.27%32 892